Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.53 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL242758 | 1.00 | CCR3 (0.62) | CCR3CXCR4ACHEALDH1A1BCHE | |
| SCHEMBL1180490 | 1.00 | CCR3 (0.62) | CCR3CXCR4ACHEALDH1A1BCHE | |
| SCHEMBL3172847 | 0.91 | CYP2D6 (0.62) | CCR3CXCR4ALDH1A1CYP2D6ATM | |
| SCHEMBL992110 | 0.90 | CYP2D6 (0.62) | CCR3ACHEALDH1A1BCHECYP1A2 | |
| SCHEMBL1061878 | 0.89 | CCR3 (0.71) | CCR3CXCR4ACHEALDH1A1BCHE | |
| Hydrochloric Acid SCHEMBL31687488 | 0.89 | CYP2D6 (0.60) | CCR3ACHEALDH1A1BCHECYP1A2 | |
| SCHEMBL15064714 | 0.89 | CCR3 (0.57) | CCR3CXCR4ACHEALDH1A1BCHE | |
| Hydrochloric Acid SCHEMBL4882236 | 0.88 | CCR3 (0.69) | CCR3CXCR4ACHEALDH1A1BCHE | |
| Hydrochloric Acid SCHEMBL7838855 | 0.88 | CCR3 (0.69) | CCR3CXCR4ACHEALDH1A1BCHE | |
| SCHEMBL5969011 | 0.87 | CCR3 (0.58) | CCR3CXCR4ACHEALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903372-B | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN LA ROCHE | 2014-06-18 | — | — | CN | disclosed |
| US-7897627-B2 | Heteroaryl derivatives as orexin receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| US-7432271-B2 | Pyrazolyl inhibitors of 15-lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005047293-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-6890938-B2 | Indole-type inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| US-20050070589-A1 | Pyrazolyl inhibitors of 15- lipoxygenase | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | disclosed |
| EP-1339708-A2 | INDOLE-TYPE INHIBITORS OF P38 KINASE | Scios Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | SCIOS, INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002044168-A2 | INDOLE-TYPE INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CCR3 3714/4885CXCR4 4067/4885ACHE 403/4885 |
| US-20050070589-A1 | Pyrazolyl inhibitors of 15- lipoxygenase | ALOX15, ALOX5, ALOX15B | CCR3 2521/4885CXCR4 3014/4885ACHE 2188/4885 |
| US-20070191333-A1 | Antibacterial agents | MRPL21, RPN2, FBL | CCR3 4258/4885CXCR4 3938/4885ACHE 423/4885 |
| US-20090163485-A1 | HETEROARYL DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, MTNR1A | CCR3 965/4885CXCR4 755/4885ACHE 4160/4885 |
| US-20030100588-A1 | Indole-type inhibitors of p38 kinase | CNKSR1, MAPK1, MAP2K6 | CCR3 652/4885CXCR4 453/4885ACHE 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.